Buspirone in social phobia

Franklin R. Schneier, Jihad B. Saoud, Raphael Campeas, Brian A. Fallon, Eric Hollander, Jeremy Coplan, Michael R. Liebowitz

Research output: Contribution to journalArticle

68 Citations (Scopus)

Abstract

The novel anxiolytic agent buspirone has been shown to be effective in generalized anxiety disorder, but its utility in phobic disorders is less clear. We examined its efficacy in social phobia in a 12-week open trial. Twenty-one patients who met DSM-III-R criteria for social phobia and who did not respond to 1 week of single-blind placebo were treated with buspirone, and 17 completed a mini-mum of 2 weeks of treatment. Twelve of these 17 patients met criteria for the generalized subtype of social phobia. At week 12, 8(47%) of the 17 patients were rated much to very much improved in social phobia symptoms on the Clinical Global Impression Scale. Of the 12 patients who were able to tolerate a dose of 45 mg/day or more, 9 (67%) were at least much improved. Significant improvement was noted on measures of social anxiety and avoidance of social situations. Ratings of generalized anxiety and depression, which were low at baseline, did not change significantly during treatment. The results suggest that buspirone may have modest efficacy in the treatment of social phobia, but confirmation in a placebo-controlled trial is required.

Original languageEnglish (US)
Pages (from-to)251-256
Number of pages6
JournalJournal of Clinical Psychopharmacology
Volume13
Issue number4
StatePublished - 1993
Externally publishedYes

Fingerprint

Buspirone
Anxiety
Placebos
Phobic Disorders
Anti-Anxiety Agents
Anxiety Disorders
Diagnostic and Statistical Manual of Mental Disorders
Social Phobia
Depression
Therapeutics

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Psychiatry and Mental health
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Schneier, F. R., Saoud, J. B., Campeas, R., Fallon, B. A., Hollander, E., Coplan, J., & Liebowitz, M. R. (1993). Buspirone in social phobia. Journal of Clinical Psychopharmacology, 13(4), 251-256.

Buspirone in social phobia. / Schneier, Franklin R.; Saoud, Jihad B.; Campeas, Raphael; Fallon, Brian A.; Hollander, Eric; Coplan, Jeremy; Liebowitz, Michael R.

In: Journal of Clinical Psychopharmacology, Vol. 13, No. 4, 1993, p. 251-256.

Research output: Contribution to journalArticle

Schneier, FR, Saoud, JB, Campeas, R, Fallon, BA, Hollander, E, Coplan, J & Liebowitz, MR 1993, 'Buspirone in social phobia', Journal of Clinical Psychopharmacology, vol. 13, no. 4, pp. 251-256.
Schneier FR, Saoud JB, Campeas R, Fallon BA, Hollander E, Coplan J et al. Buspirone in social phobia. Journal of Clinical Psychopharmacology. 1993;13(4):251-256.
Schneier, Franklin R. ; Saoud, Jihad B. ; Campeas, Raphael ; Fallon, Brian A. ; Hollander, Eric ; Coplan, Jeremy ; Liebowitz, Michael R. / Buspirone in social phobia. In: Journal of Clinical Psychopharmacology. 1993 ; Vol. 13, No. 4. pp. 251-256.
@article{29fd574b21e444da9af6a5d92367aa45,
title = "Buspirone in social phobia",
abstract = "The novel anxiolytic agent buspirone has been shown to be effective in generalized anxiety disorder, but its utility in phobic disorders is less clear. We examined its efficacy in social phobia in a 12-week open trial. Twenty-one patients who met DSM-III-R criteria for social phobia and who did not respond to 1 week of single-blind placebo were treated with buspirone, and 17 completed a mini-mum of 2 weeks of treatment. Twelve of these 17 patients met criteria for the generalized subtype of social phobia. At week 12, 8(47{\%}) of the 17 patients were rated much to very much improved in social phobia symptoms on the Clinical Global Impression Scale. Of the 12 patients who were able to tolerate a dose of 45 mg/day or more, 9 (67{\%}) were at least much improved. Significant improvement was noted on measures of social anxiety and avoidance of social situations. Ratings of generalized anxiety and depression, which were low at baseline, did not change significantly during treatment. The results suggest that buspirone may have modest efficacy in the treatment of social phobia, but confirmation in a placebo-controlled trial is required.",
author = "Schneier, {Franklin R.} and Saoud, {Jihad B.} and Raphael Campeas and Fallon, {Brian A.} and Eric Hollander and Jeremy Coplan and Liebowitz, {Michael R.}",
year = "1993",
language = "English (US)",
volume = "13",
pages = "251--256",
journal = "Journal of Clinical Psychopharmacology",
issn = "0271-0749",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Buspirone in social phobia

AU - Schneier, Franklin R.

AU - Saoud, Jihad B.

AU - Campeas, Raphael

AU - Fallon, Brian A.

AU - Hollander, Eric

AU - Coplan, Jeremy

AU - Liebowitz, Michael R.

PY - 1993

Y1 - 1993

N2 - The novel anxiolytic agent buspirone has been shown to be effective in generalized anxiety disorder, but its utility in phobic disorders is less clear. We examined its efficacy in social phobia in a 12-week open trial. Twenty-one patients who met DSM-III-R criteria for social phobia and who did not respond to 1 week of single-blind placebo were treated with buspirone, and 17 completed a mini-mum of 2 weeks of treatment. Twelve of these 17 patients met criteria for the generalized subtype of social phobia. At week 12, 8(47%) of the 17 patients were rated much to very much improved in social phobia symptoms on the Clinical Global Impression Scale. Of the 12 patients who were able to tolerate a dose of 45 mg/day or more, 9 (67%) were at least much improved. Significant improvement was noted on measures of social anxiety and avoidance of social situations. Ratings of generalized anxiety and depression, which were low at baseline, did not change significantly during treatment. The results suggest that buspirone may have modest efficacy in the treatment of social phobia, but confirmation in a placebo-controlled trial is required.

AB - The novel anxiolytic agent buspirone has been shown to be effective in generalized anxiety disorder, but its utility in phobic disorders is less clear. We examined its efficacy in social phobia in a 12-week open trial. Twenty-one patients who met DSM-III-R criteria for social phobia and who did not respond to 1 week of single-blind placebo were treated with buspirone, and 17 completed a mini-mum of 2 weeks of treatment. Twelve of these 17 patients met criteria for the generalized subtype of social phobia. At week 12, 8(47%) of the 17 patients were rated much to very much improved in social phobia symptoms on the Clinical Global Impression Scale. Of the 12 patients who were able to tolerate a dose of 45 mg/day or more, 9 (67%) were at least much improved. Significant improvement was noted on measures of social anxiety and avoidance of social situations. Ratings of generalized anxiety and depression, which were low at baseline, did not change significantly during treatment. The results suggest that buspirone may have modest efficacy in the treatment of social phobia, but confirmation in a placebo-controlled trial is required.

UR - http://www.scopus.com/inward/record.url?scp=0027325907&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027325907&partnerID=8YFLogxK

M3 - Article

VL - 13

SP - 251

EP - 256

JO - Journal of Clinical Psychopharmacology

JF - Journal of Clinical Psychopharmacology

SN - 0271-0749

IS - 4

ER -